{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T21:17:19Z","timestamp":1774905439451,"version":"3.50.1"},"reference-count":27,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"published-print":{"date-parts":[[2024,8,2]]},"DOI":"10.1080\/17425255.2024.2373095","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T07:26:03Z","timestamp":1719991563000},"page":"713-718","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetic evaluation of ibrexafungerp for the treatment of vulvovaginal candidiasis and beyond"],"prefix":"10.1080","volume":"20","author":[{"given":"Gage M.","family":"Dixon","sequence":"first","affiliation":[{"name":"Oregon Health and Science University","place":["Portland, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"II","given":"James S.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University","place":["Portland, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"George R.","family":"Thompson","sequence":"additional","affiliation":[{"name":"University of California-Davis Medical Center","place":["Sacramento, USA"]},{"name":"University of California Davis-Medical Center","place":["Sacramento, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(18)30103-8"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/lgt.0b013e318273e8cf"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof6010027"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-019-05228-3"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8020144"},{"key":"e_1_3_4_8_1","volume-title":"Ibrexafungerp [package insert]","year":"2022","unstructured":"Ibrexafungerp [package insert]. Jersey City (NJ): Scynexis; 2022."},{"key":"e_1_3_4_9_1","volume-title":"Oteseconazole [package insert]","year":"2022","unstructured":"Oteseconazole [package insert]. Durham (NC): Mycovia Pharmaceuticals; 2022."},{"key":"e_1_3_4_10_1","volume-title":"Fluconazole [package insert]","year":"2023","unstructured":"Fluconazole [package insert]. New York City (NY): Pfizer; 2023."},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00244-18"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00161-17"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00833-17"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00435-17"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00234-15"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02068-16"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02119-18"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02611-18"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.04445-14"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01075-23"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab750"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.16972"},{"key":"e_1_3_4_23_1","unstructured":"Phase 3 study of oral ibrexafungerp (SCY-078) Vs. Placebo in subjects with recurrent vulvovaginal candidiasis (VVC) (CANDLE). CTG Labs - NCBI. [cited 2024 Jan 4]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04029116?tab=results"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab841"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.064"},{"key":"e_1_3_4_26_1","volume-title":"The American Society for Microbiology","author":"Murphy G","year":"2017","unstructured":"Murphy G, Darpo B, Marbury T, et al. Lack of an effect of SCY-078 a novel antifungal agent on QTc interval in healthy subject. The American Society for Microbiology; New Orleans; 2017."},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1146"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.588"},{"key":"e_1_3_4_29_1","unstructured":"SCYNEXIS issues a voluntary nationwide recall of BREXAFEMME\u00ae (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial \u00dflactam drug substance. 2023. https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/scynexis-issues-voluntary-nationwide-recall-brexafemmer-ibrexafungerp-tablets-due-potential-cross"}],"container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2024.2373095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T09:48:37Z","timestamp":1750326517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2024.2373095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,2]]}},"alternative-id":["10.1080\/17425255.2024.2373095"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2024.2373095","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}